Volociximab (M200), the first humanized IgG4 monoclonal antibody against α5β1, binds with high affinity to block the interaction between α5β1 and fibronectin (FN), thereby inhibiting tumor-associated angiogenesis and endothelial-cell proliferation (Ramakrishnan et al., 2006; Pantano et al., 2021). The gene discussed is FN1; the disease is neoplasm.